Pemigatinib
VIDEO: Strategic sequencing of targeted therapies key in cholangiocarcinoma
In this video, Lionel Aurelien Kankeu Fonkoua, MD, discusses the impact of sequencing targeted therapies when treating patients with cholangiocarcinoma.
Anticancer-drug dose changes, discontinuations lead to $4,290 in pill wastage per patient
Wastage from dose reduction or discontinuation of the most common oral anticancer drugs costs a mean of $4,290 per patient, results of a retrospective study showed.
VIDEO: Emergence of targeted therapies ‘broadened treatment options’ for cholangiocarcinoma
In this video, Sumera I. Ilyas, MBBS, gastroenterologist, physician-scientist and transplant hepatologist with Mayo Clinic, discusses the current landscape of targeted treatment in cholangiocarcinoma.
FDA approves pemigatinib for myeloid/lymphoid neoplasms with FGFR1 rearrangement
The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and rearrangement of fibroblast growth factor receptor 1, according to a press release from the agent’s manufacturer.
FDA approves first targeted therapy for cholangiocarcinoma
The FDA granted accelerated approval to pemigatinib for treatment of certain adults with previously treated unresectable cholangiocarcinoma.